NCT04450108View on ClinicalTrials.gov

Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients

NACompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

December 18, 2020

Study Completion Date

April 13, 2021

Conditions
AsthmaAsthma in Children
Interventions
DIAGNOSTIC_TEST

Vivatmo pro FeNO Test

Breath gas analysis

Trial Locations (6)

21162

Chesapeake Clinical Research, Inc., White Marsh

27607

North Carolina Clinical Research, Raleigh

35209

Clinical Research Center of Alabama, Birmingham

63141

The Clinical Research Center, LLC, St Louis

76712

Allergy Asthma Research Institute, Waco

93301

Kern Research, Inc., Bakersfield

Sponsors

Collaborators (1)

Global BioClinical
All Listed Sponsors
collaborator

Global BioClinical

INDUSTRY

lead

Bosch Healthcare Solutions GmbH

INDUSTRY

NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients | Biotech Hunter | Biotech Hunter